Dr. Vered Padler-Karavani

מח חקר התא ואימונולוגיה סגל אקדמי בכיר
Dr. Vered Padler-Karavani
Phone: 03-6406737
Another phone: 03-6405064
Fax: 03-6422046
Office: Britannia-Porter, 306




Post-doctoral fellow; Glycobiology, University of California-San Diego

2000-2005 Ph.D.; Biochemistry, Tel Aviv University
1997-1999 M.Sc.; Biochemistry (magna cum laude), Tel Aviv University
1994-1997 B.Sc.; Biology (magna cum laude); Tel Aviv University


Academic Appointments:

2013-present Senior Lecturer; Department of Cell Research & Immunology, Tel Aviv University
2010-2012 Assistant Project Scientist; Department of Cellular & Molecular Medicine, University of California-San Diego


Honors & Awards:

2013 AAI Early Career Faculty Travel Grant
2009-2011 Edmond J. Safra-ISEF postdoctoral fellowship
2005, 2007 HSBC-ISEF postdoctoral fellowship (awarded to only 10 outstanding international scholars per year)
2004 The Arie and Keren Shenkar award for excellence in studies and teaching.


Research Interests

Our lab is studying the mechanisms that govern glycan immune recognition and responses in animal models and humans, both in vitro and in vivo. We combine glycobiology, immunology, biotechnology and cancer research, and use cutting edge technologies within these disciplines, including glycan microarray and glyco-nanotechnology.


Current interests include:  Immunological mechanisms of unique anti-carbohydrate antibodies; Glycoimmunology in xenotransplantation, as members of the EU TRANSLINK consorsium; Anti-carbohydrate antibodies in mucosal secretions and sera; Development novel diagnostics and therapeutics to chronic inflammation mediated diseases; Development of bio-nanotechnology tools based on glycan recognition.


Recent Publications

Amon R, Reuven EM, Leviatan Ben-Arye S, Padler-Karavani V. (2014). Glycans in immune recognition and responseCarbohydr Res. 389:115-22.


Padler-Karavani V#, Hurtado-Ziola N#, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, Verhagen A, Nizet V, Chen X, Varki N, Varki A, Angata T. (2014). Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primatesFASEB J. 28(3):1280-93 (# equally contributed). UCSD blog: http://ucsdhealthsciences.tumblr.com/post/77737274933/the-red-queen-effect-writ-small-in-what-amountsFeatured on FASEB March 2014 issue; “Scientists Learn How Pathogens Hack Our Immune Systems To Go Undetected”: http://www.eurekalert.org/pub_releases/2014-02/foas-slh022714.php


Padler-Karavani V. (2014). Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicineCancer Lett. 28;352(1):102-12.


Scobie L#, Padler-Karavani V#, Le Bas-Bernardet S, Crossan C, Blaha J, Matouskova M, Hector RD, Cozzi E, Vanhove B, Charreau B, Blancho G, Bourdais L, Tallacchini M, Ribes JM, Yu H, Chen X, Kracikova J, Broz L, Hejnar J, Vesely P, Takeuchi Y, Varki A, Soulillou JP. (2013). Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenograftsJ Immunol. 191(6):2907-15 (# equally contributed).


Kikkeri R, Padler-Karavani V, Diaz S, Verhagen A, Yu H, Cao H, Langereis MA, De Groot RJ, Chen X, Varki A. (2013). Quantum dot nanometal surface energy transfer based biosensing of sialic acid compositions and linkages in biological samplesAnal Chem. 85(8):3864-70


Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. (2013). A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS One. 8(3):e58443.


Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, Verhagen A, Reid C, Lari M, Rizzi E, Balsamo C, Corti G, De Bellis G, Longo L; NISC Comparative Sequencing Program, Beggs W, Caramelli D, Tishkoff SA, Hayakawa T, Green ED, Mullikin JC, Nizet V, Bui J, Varki A. (2012). Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.Proc Natl Acad Sci 109(25):9935-40. UCSD News release: http://health.ucsd.edu/news/releases/Pages/2012-06-04-infectious-disease-shaped-human-origins.aspx


Padler-Karavani V#, Song X#, Yu H, Hurtado-Ziola N, Huang S, Muthana S, Chokhawala HA, Cheng J, Verhagen A, Langereis MA, Kleene R, Schachner M, de Groot RJ, Lasanajak Y, Matsuda H, Schwab R, Chen X, Smith DF, Cummings RD, Varki A. (2012). Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem. 287(27):22593-608 (# equally contributed).


Lu Q#, Padler-Karavani V#, Yu H, Chen X, Wu S-L, Varki A and Hancock WS. (2012) LC-MS analysis of polyclonal human anti-Neu5Gc Xeno-autoantibodies IgG subclass and partial sequence using multi-step IVIG affinity purification and multi-enzymatic digestionAnal Chem 84(6):2761-8 (# equally contributed).


Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancerCancer Res. 71(9):3352-63.


Padler-Karavani V, Varki A. (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection riskXenotransplantation. 18(1):1-5.


Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S and Varki A. (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsNat Biotech. 28(8):863-7. 


Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V and Varki A. (2010) Novel mechanism for the generation of human xeno-auto-antibodies against the non-human sialic acid N-glycolylneuraminic acidJ Exp Med. 207(8): 1637-1646.


Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM and Varki A. (2009) Evidence for a Novel Human-specific Xeno-Auto-Antibody Response Against Vascular Endothelium. Blood. 114(25): 5225-35.


Hedlund M, Padler-Karavani V, Varki N, and Varki A. (2008) Evidence for a Human-Specific Mechanism for Diet and Antibody-Mediated Inflammation in Carcinoma Progression. Proc Natl Acad Sci U S A. 105(48): 18936-41.


Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X and Varki A. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology. 18(10): 818-30.


Aviezer-Hagai K#, Padler-Karavani V#, Nelson N. (2003) Biochemical support for the V-ATPase rotary mechanism: antibody against HA-tagged Vma7p or Vma16p but not Vma10p inhibits activity. J Exp Biol. 206: 3227-37. (# equally contributed).


Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
Developed by
UI/UX Basch_Interactive